Pathstone Holdings’s United Therapeutics UTHR Stock Holding History

Pathstone Holdings’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.78M	Buy	5,129 +301	+6%	+$170K	0.01%	929
2026 Q1	$2.86M	Buy	4,828 +385	+9%	+$192K	0.01%	842
2025 Q4	$2.16M	Buy	4,443 +60	+1%	+$27.9K	0.01%	979
2025 Q3	$1.84M	Buy	4,383 +191	+5%	+$64.2K	0.01%	1081
2025 Q2	$1.2M	Buy	4,192 +112	+3%	+$33.5K	﹤0.01%	1296
2025 Q1	$1.26M	Buy	4,080 +45	+1%	+$15.4K	0.01%	1252
2024 Q4	$1.42M	Sell	4,035 -83	-2%	-$30.5K	0.01%	1171
2024 Q3	$1.48M	Buy	4,118 +163	+4%	+$55.1K	0.01%	1157
2024 Q2	$1.26M	Buy	3,955 +328	+9%	+$86.8K	0.01%	1189
2024 Q1	$833K	Buy	3,627 +389	+12%	+$87.8K	﹤0.01%	1392
2023 Q4	$712K	Buy	+3,238	New	+$746K	﹤0.01%	1282

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Pathstone Holdings's UTHR Position: Q2 2026 in Review

Pathstone Holdings increased its United Therapeutics (UTHR) stake by 6.2% in Q2 2026, buying an estimated $170K and bringing the position to 5,129 shares worth $2.78M. The position accounts for 0.01% of the portfolio, ranked #929.

Pathstone Holdings first reported a position in UTHR in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.86M in Q1 2026. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Pathstone Holdings held 5,129 shares of United Therapeutics worth $2.78M as of Q2 2026.
Pathstone Holdings bought 301 United Therapeutics shares in Q2 2026, an estimated $170K.
United Therapeutics made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #929 holding.
Pathstone Holdings first reported a position in United Therapeutics in Q4 2023 and has held it in 11 quarters since.
Pathstone Holdings's United Therapeutics position peaked at $2.86M in Q1 2026.
875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.